Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
31
ZTS Quote, Financials, Valuation and Earnings
Last price:
$126.75
Seasonality move
:
-1.57%
Day range:
$128.70 - $131.13
52-week range:
$115.25 - $177.40
Dividend yield:
1.55%
P/E ratio:
21.79x
P/S ratio:
6.15x
P/B ratio:
10.56x
Volume:
4.4M
Avg. volume:
5.7M
1-year change:
-22.03%
Market cap:
$57B
Revenue:
$9.3B
EPS (TTM):
$5.94
Analysts' Opinion
-
Consensus RatingZoetis, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $158.22, Zoetis, Inc. has an estimated upside of 22.32% from its current price of $129.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $130.00 representing 100% downside risk from its current price of $129.35.
Fair Value
-
According to the consensus of 15 analysts, Zoetis, Inc. has 22.32% upside to fair value with a price target of $158.22 per share.
ZTS vs. S&P 500
-
Over the past 5 trading days, Zoetis, Inc. has overperformed the S&P 500 by 1.21% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Zoetis, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zoetis, Inc. has grown year-over-year revenues for 39 quarters straight. In the most recent quarter Zoetis, Inc. reported revenues of $2.4B.
Earnings Growth
-
Zoetis, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Zoetis, Inc. reported earnings per share of $1.63.
Enterprise value:
62.2B
EV / Invested capital:
--
Price / LTM sales:
6.15x
EV / EBIT:
17.59x
EV / Revenue:
6.62x
PEG ratio (5yr expected):
1.88x
EV / Free cash flow:
27.76x
Price / Operating cash flow:
25.81x
Enterprise value / EBITDA:
15.45x
Gross Profit (TTM):
$6.6B
Return On Assets:
18.33%
Net Income Margin (TTM):
28.21%
Return On Equity:
52.95%
Return On Invested Capital:
22.32%
Operating Margin:
39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $8.4B | $9.2B | $9.4B | $2.4B | $2.4B | |
| Gross Profit | $5.7B | $6.3B | $6.6B | $1.7B | $1.7B | |
| Operating Income | $3.1B | $3.3B | $3.5B | $920M | $936M | |
| EBITDA | $3.5B | $3.8B | $4B | $1B | $1.1B | |
| Diluted EPS | $4.92 | $5.32 | $5.94 | $1.50 | $1.63 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.7B | $6.6B | $6.2B | $6.3B | $6.6B | |
| Total Assets | $13.7B | $13.7B | $14.1B | $14.4B | $15.2B | |
| Current Liabilities | $1.5B | $2.9B | $1.6B | $1.7B | $1.8B | |
| Total Liabilities | $9B | $9B | $9B | $9.1B | $9.8B | |
| Total Equity | $4.7B | $4.7B | $5.1B | $5.2B | $5.4B | |
| Total Debt | $6.8B | $6.7B | $6.7B | $6.8B | $7.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.2B | $2.9B | $2.9B | $951M | $938M | |
| Cash From Investing | -$1B | -$651M | -$456M | -$178M | -$160M | |
| Cash From Financing | -$1.9B | -$2.3B | -$2.1B | -$628M | -$134M | |
| Free Cash Flow | $1.5B | $2.3B | $2.2B | $784M | $805M | |
ZTS
Sector
Market Cap
$57B
$28.5M
Price % of 52-Week High
72.91%
51.36%
Dividend Yield
1.55%
0%
Shareholder Yield
3.83%
-1.55%
1-Year Price Total Return
-22.03%
-20%
Beta (5-Year)
0.970
0.497
Dividend yield:
1.55%
Annualized payout:
$1.73
Payout ratio:
30.74%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$126.82
200-day SMA
Sell
Level
$146.90
Bollinger Bands (100)
Sell
Level
123.56 - 150.26
Chaikin Money Flow
Buy
Level
188M
20-day SMA
Buy
Level
$123.08
Relative Strength Index (RSI14)
Buy
Level
63.72
ADX Line
Buy
Level
17.96
Williams %R
Sell
Level
-17.0989
50-day SMA
Buy
Level
$125.54
MACD (12, 26)
Buy
Level
0.95
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
250.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.4612)
Buy
CA Score
(Annual)
Level (0.1382)
Buy
Beneish M-Score
(Annual)
Level (-2.6183)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.788)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.
Stock Forecast FAQ
In the current month, ZTS has received 7 Buy ratings 8 Hold ratings, and 0 Sell ratings. The ZTS average analyst price target in the past 3 months is $158.22.
-
Where Will Zoetis, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zoetis, Inc. share price will rise to $158.22 per share over the next 12 months.
-
What Do Analysts Say About Zoetis, Inc.?
Analysts are divided on their view about Zoetis, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zoetis, Inc. is a Sell and believe this share price will drop from its current level to $130.00.
-
What Is Zoetis, Inc.'s Price Target?
The price target for Zoetis, Inc. over the next 1-year time period is forecast to be $158.22 according to 15 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is ZTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zoetis, Inc. is a Hold. 8 of 15 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ZTS?
You can purchase shares of Zoetis, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zoetis, Inc. shares.
-
What Is The Zoetis, Inc. Share Price Today?
Zoetis, Inc. was last trading at $126.75 per share. This represents the most recent stock quote for Zoetis, Inc.. Yesterday, Zoetis, Inc. closed at $129.35 per share.
-
How To Buy Zoetis, Inc. Stock Online?
In order to purchase Zoetis, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ZTS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ZTS
Sector
P/E ratio
21.79x
24.20x
PEG ratio
1.88x
-0.01x
P/B ratio
10.56x
1.84x
Price / LTM sales
6.15x
1.60x
Growth Metrics
ZTS
Sector
Revenue growth
0.5%
4.62%
Earnings growth
8.17%
10.88%
Revenue (5-year growth)
8.14%
6.45%
Earnings forecast
$1.40
-$0.18
Profitability
ZTS
Sector
Profitability FY 2024
$6.4B
$3.6M
Return on invested capital
22.32%
-32.02%
Return on assets
18.33%
-28.31%
Return on equity
52.95%
-38%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Feb
3
Balance Sheet
ZTS
Sector
Total cash
$2.1B
$26.1M
Short term investments
--
$25.7M
Total assets
$14.2B
$76.6M
Long term debt
$7.3B
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
